The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
ID: 359015Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359015
Timeline
    Description

    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development," aimed at enhancing the understanding of complex metabolic diseases, particularly Type 2 Diabetes (T2D). This initiative seeks to renew the AMP CMD UM1 program for an additional five years, focusing on the aggregation and collation of genetic data related to T2D and its complications, thereby facilitating research and therapeutic advancements in the field. The program is critical for leveraging human genetics to uncover disease mechanisms and potential biomarkers, with an estimated total funding of $3 million and the expectation of one award. Interested applicants, including small businesses and various organizations, should contact Dr. Norann Zaghloul at Norann.zaghloul@nih.gov or call 301-435-6677 for further details, with proposals due by March 1, 2026, and awards anticipated by December 1, 2026.

    Point(s) of Contact
    Norann Zaghloul, PhD National Institute of Diabetes and Digestive and Kidney Diseases
    (301) 435-6677
    Norann.zaghloul@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Single Source: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity for the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Clinical Trial Data Processing, Analysis, and Coordination Center. This initiative aims to renew support for core program activities, including the management, direction, and coordination of data processing and analysis to bolster the AMP SCZ Clinical Trial Network. The program is crucial for advancing research on pharmacological interventions for psychosis and requires collaboration among experts in clinical research and bioinformatics. The estimated total funding for this opportunity is $12 million, with one award anticipated. Interested applicants can reach out to Dr. Suzanne Garcia at suzanne.garcia@nih.gov or call 202-345-1260 for further information. Key dates include an estimated synopsis post date of September 24, 2025, and a close date of October 24, 2025, with project activities expected to commence on July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Environmental Determinants of Diabetes in The Young Study (TEDDY) Data Coordinating Center (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for a single source cooperative agreement to support the continuation of the Environmental Determinants of Diabetes in The Young (TEDDY) Data Coordinating Center (DCC). This funding aims to facilitate the ongoing analysis of samples from a second case-control cohort and to provide resources for the closeout of the TEDDY study, which is crucial for understanding the prevention and treatment of type 1 diabetes. The total estimated funding for this opportunity is $6 million, with one award anticipated, and interested applicants can reach out to Dr. Arthur Castle at castlea@niddk.nih.gov or by phone at 301-594-7719 for further information. The estimated synopsis post date is September 26, 2025, with a closing date of October 26, 2025, and the project is expected to commence on July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    ancient DNA for Modern Genomics (aDMG) Data Generation and Resource Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming opportunity for a cooperative agreement to establish an ancient DNA for Modern Genomics (aDMG) Data Generation and Resource Center. This initiative aims to create an ethical resource of ancient and historical human DNA data to enhance research on contemporary human traits and biology, producing high-quality whole-genome sequence data from approved sources and integrating it into a centralized data portal. The estimated total program funding is $2,750,000, with one award expected, and interested applicants, particularly those with expertise in DNA sequencing, computational genomics, and human evolution, are encouraged to prepare for the application process. For further inquiries, potential applicants can contact Jennifer Troyer at jennifer.troyer@nih.gov or by phone at 301-312-3276. The estimated synopsis post date is December 1, 2025, with applications expected to close by March 2, 2026, and project start anticipated on July 1, 2026.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Single Source for Continuation of the Integrated Islet Distribution Program (UC4)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for a single source cooperative agreement to continue the Integrated Islet Distribution Program (IIDP), with an estimated total funding of $3.3 million. This program aims to facilitate the distribution of human islets to biomedical researchers, thereby supporting critical research in diabetes by managing islet availability, investigator eligibility, and overseeing standardized analyses of islet preparations. Interested applicants, particularly those with expertise in live cell distribution and human islet biology, are encouraged to prepare for the upcoming application process, with the estimated synopsis posting date set for June 25, 2025, and the anticipated award date on July 1, 2026. For further inquiries, potential applicants can contact Dr. Thomas L. Eggerman at eggermant@nih.gov or by phone at 301-594-8814.
    ancient DNA for Modern Genomics (aDMG) Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to solicit applications for the establishment of an ancient DNA for Modern Genomics (aDMG) Coordination Center, aimed at creating an ethical resource of ancient and historical human DNA data to enhance research on contemporary human traits and biology. The initiative will involve collaboration with researchers and local communities to identify and oversee sources of ancient DNA, facilitating program activities across various components. This funding opportunity, categorized under health-related discretionary grants, has an estimated total program funding of $1.5 million, with one award anticipated. Interested applicants can reach out to Jennifer Troyer at jennifer.troyer@nih.gov or call 301-312-3276 for further information, with the estimated synopsis post date set for December 1, 2025, and applications expected to be accepted until March 2, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.